Increased risk for attacks seen in women younger than 35 years, those with eosinophilia, those with lower corticosteroid use.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

The prescription device is a wearable belt that includes a motor designed to transmit low amplitude, high frequency vibration to the spine and hips.

The Teal Wand is an at-home vaginal self-collection device intended to test for 14 types of high-risk HPV that have the ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species, which are generally elevated in ocular and systemic inflammatory disease.

New epinephrine nasal spray dosage approved for pediatrics; FDA agree to review semaglutide for weight management; wearable defibrillator cleared to ...

In a recent study, protective association lasted for up to eight years, with greatest reduction seen at two to three years postvaccination.